Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Stockhouse Bullboard Content Management Changes

<< Previous

Bullboard Posts

Next >>

Comment by MrMugsyon Dec 01, 2022 8:55am

144 Views

Post# 35142419

RE:RE:Stockhouse Bullboard Content Management Changes

This site is designed for debate around potential misinformation Duster.
Just stay focused on ATE.

-------------------

Note: Today is Dec 1.

Indomethacin/Ketotifen P3 COVID trial is due to end today (give-or-take).
Some clues may come out of this trial re. our indomethacin based Antiviral and the potential for lung inflammation.

Further down the road, I'm assuming Antiviral/IBD combonation may need to be tested for other autoimmune opportunities as well.

<< Previous

Bullboard Posts

Next >>

From now on, dynaCERT instead of Bitcoin or NVIDIA?